75938-36-2 Usage
Uses
Used in Pharmaceutical Industry:
3,7-Dideazaguanine is used as a potential therapeutic agent for cancer and viral treatments due to its ability to interfere with the synthesis of DNA and RNA, inhibiting the growth and replication of cancer cells and certain viruses.
Used in Cancer Treatment:
3,7-Dideazaguanine is used as an anti-cancer agent, targeting the growth and replication of cancer cells by interfering with the synthesis of DNA and RNA, thereby inhibiting their proliferation.
Used in Viral Treatment:
3,7-Dideazaguanine is used as an anti-viral agent, targeting the replication of certain viruses by interfering with the synthesis of DNA and RNA, thereby inhibiting their growth and spread.
Research on 3,7-dideazaguanine is ongoing, with the aim of further elucidating its potential as a therapeutic agent in cancer and viral treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 75938-36-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,9,3 and 8 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 75938-36:
(7*7)+(6*5)+(5*9)+(4*3)+(3*8)+(2*3)+(1*6)=172
172 % 10 = 2
So 75938-36-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H7N3O/c8-6-3-5-4(1-2-9-5)7(11)10-6/h1-3,9H,(H3,8,10,11)
75938-36-2Relevant academic research and scientific papers
Synthesis and Biological Evaluation of 6-Amino-1H-pyrrolopyridin-4(5H)-one (3,7-Dideazaguanine)
Schneller, Stewart W.,Luo, Jiann-Kuan,Hosmane, Ramachandra S.,Clerqu, Erik De,Stoeckler, Johanna D.,et al.
, p. 1737 - 1739 (2007/10/02)
The synthesis of 6-amino-1H-pyrrolopyridin-4(5H)-one (3,7-dideazaguanine, 2) has been accomplished from 3-(ethoxycarbonyl)pyrrole-2-acetonitrile.In contrast to 3-deazaguanine, compound 2 did not show any antitumor, antiviral. or antibacterial properties.Furthermore, it was not a substrate for hypoxanthine-guanine phosphoribosyltransferase or purine nucleoside phosphorylase.
